Cardiac sarcoidosis is a rare and often underdiagnosed condition characterized by the presence of inflammatory cells, known as granulomas, within the heart tissue. Sarcoidosis itself is a multisystem inflammatory disorder that can affect various organs, but when it involves the heart, it becomes particularly challenging due to the potential for serious complications. The exact cause of cardiac sarcoidosis remains unclear, but it is believed to involve an abnormal immune response. Symptoms can vary widely and may include arrhythmias, heart failure, and conduction abnormalities. Diagnosing cardiac sarcoidosis can be complex, often requiring a combination of clinical evaluation, imaging studies such as cardiac MRI or PET scans, and occasionally, cardiac biopsy. Timely diagnosis is crucial, as cardiac sarcoidosis can lead to significant morbidity and mortality if left untreated. Treatment often includes the use of immunosuppressive medications, which are prescribed to mitigate inflammation and alleviate symptoms. Given the rarity of the condition, increased awareness and collaboration between cardiologists and other specialists are essential for improving the early detection and management of cardiac sarcoidosis.
Title : Frequency of residual risk in cardiovascular secondary prevention in patients treated at the Reina Fabiola University Clinic
Agustin Joison, Cordoba Catholic University, Argentina
Title : Revolutionizing heart health through Personalized & Precision Medicine (PPM): Towards personalized cardiovascular prevention, precision cardiac care & rehabilitation via optimizing Cardiac Hospital Networks
Sergey Suchkov, N. D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Title : Antibody-proteases as unique biomarkers, potential targets and translational tools of the next step generation to be used in personalized and precision cardiology practice
Sergey Suchkov, N. D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Title : Investigation of bergapten’s pharmacological activity against doxorubicin induced cardiotoxicity: supporting evidence from cellular and animal models
Bijoy Krishna Banik, National Institute of Pharmaceutical Education and Research (NIPER)-Guwahati, India